title: Clinical trials update from the European Society of Cardiology meeting 2005: CARE-HF extension study, ESSENTIAL, CIBIS-III, S-ICD, ISSUE-2, STRIDE-2, SOFA, IMAGINE, PREAMI, SIRIUS-II and ACTIVE.
abstract: This article provides information and a commentary on trials presented at the European Society of Cardiology meeting held in September 2005, relevant to the pathophysiology, prevention and treatment of heart failure. All reports should be considered as preliminary data, as analyses may change in the final publication. In the CARE-HF extension study, the benefits of cardiac resynchronisation therapy (CRT) observed in the original study were maintained over an increased follow-up period. A study of oral enoximone (25-50 mg t.i.d.) in advanced heart failure (ESSENTIAL) showed limited benefit compared to placebo. The CIBIS-III study showed that heart failure therapy could be safely initiated with bisoprolol followed by the addition of enalapril. A subcutaneous ICD system (S-ICD) showed potential as an alternative to a transvenous ICD. In the ISSUE-2 study, an implantable loop recorder was used to guide therapy in patients with recurrent syncope. The selective endothelin antagonist sitaxsentan improved 6-MWT and functional class in patients with pulmonary arterial hypertension in the STRIDE-2 study. In SOFA, fish oil had no beneficial effect on the incidence of life-threatening arrhythmias in patients with an ICD. In IMAGINE, quinapril showed no benefit when administered to patients following CABG. Perindopril reduced cardiac remodelling in post-MI patients with normal LV function in PREAMI. SIRIUS-II showed encouraging results for the use of intravenous ularitide in symptomatic decompensated chronic heart failure. The ACTIVE W study of warfarin versus aspirin plus clopidogrel in atrial fibrillation has been stopped due to superiority of warfarin.
authors.affiliation: Department of Cardiology, University of Hull, Castle Hill Hospital, Cottingham, Kingston-upon-Hull, UK.
authors.forename: John G F
authors.initials: JG
authors.lastname: Cleland
authors.forename: Alison P
authors.initials: AP
authors.lastname: Coletta
authors.forename: Mike
authors.initials: M
authors.lastname: Lammiman
authors.forename: Klaus K
authors.initials: KK
authors.lastname: Witte
authors.forename: Huan
authors.initials: H
authors.lastname: Loh
authors.forename: Mansoor
authors.initials: M
authors.lastname: Nasir
authors.forename: Andrew L
authors.initials: AL
authors.lastname: Clark
mesh_terms: D002304:Cardiac Pacing, Artificial / Q000379:methods; D002309:Cardiology; D003226:Congresses as Topic; D017147:Defibrillators, Implantable; D004656:Enalapril / Q000627:therapeutic use*; D017335:Enoximone / Q000627:therapeutic use*; D005060:Europe; D005260:Female; D005500:Follow-Up Studies; D006333:Heart Failure / Q000175:diagnosis / Q000401:mortality* / Q000628:therapy*; D006801:Humans; D007555:Isoxazoles / Q000008:administration & dosage*; D008297:Male; D016032:Randomized Controlled Trials as Topic; D018570:Risk Assessment; D012720:Severity of Illness Index; D012955:Societies, Medical; D016019:Survival Analysis; D013876:Thiophenes / Q000008:administration & dosage*; D016896:Treatment Outcome
chemical_list: D007555:Isoxazoles; D013876:Thiophenes; D004656:Enalapril; D017335:Enoximone; C106276:sitaxsentan